Q2053 Brexucabtagene car pos t
Q-Codes
Also known as: Tecartus, brexucabtagene autoleucel, CAR-T
Brexucabtagene autoleucel CAR-T cell immunotherapy for CD19-positive B-cell malignancies.
Clinical Context
Used for relapsed/refractory mantle cell lymphoma. CAR-T cells target CD19+ B-cells. Requires hospitalization and monitoring for cytokine release syndrome.
RVU Breakdown
| Work RVU | 0.00 |
| Practice Expense RVU | 0.00 |
| Malpractice RVU | 0.00 |
| Total RVU | 0.00 |
Specialties
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.